Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Fabricant Asks Supplement Industry: “What Can Be Done?”

This article was originally published in The Tan Sheet

Executive Summary

Responsible dietary supplement firms can no longer shrug off persistent industry problems caused largely by fringe firms – they must work with FDA to eradicate the problems and help consumers distinguish between the good and bad products, FDA’s Fabricant and CRN’s Mister say.

You may also be interested in...



Ingredient Safety Concerns Rise Among FDA Enforcement Priorities

Ingredient safety, new dietary ingredient notifications, adverse event reporting, claims substantiation and disease claims are all drawing FDA attention in the supplement space, Daniel Fabricant says. Compliance for good manufacturing practices still heads the priorities for enforcement, he says.

Trade Groups Expand Caffeine Labeling To Stave Off Tighter Regs

The Council for Responsible Nutrition and the American Herbal Products Association amend guidelines and requirements for labeling and marketing caffeine-containing products, going beyond the law in response to congressional and public health complaints about the ingredient’s safety.

FDA, Trade Groups Team Up To Bolster Enforcement On Tainted Supplements

FDA threatens to take "swift and strong" enforcement action without warning, including filing criminal charges, against manufacturers, suppliers and distributors of tainted supplements, according to a letter sent to industry Dec. 15.

Topics

UsernamePublicRestriction

Register

PS106633

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel